대한뉴팜

In the third quarter of 2019, Daehan New Pharm recorded cumulative sales of 98.9 billion won, representing a 10% increase compared to the same period the previous year. Operating profit rose approximately 9% year-on-year to 16.1 billion won, with an operating margin of 16.3%. Net profit also significantly increased to 9.8 billion won, reflecting a net profit margin of 9.9%.

The company is divided into four main business sectors: pharmaceutical, animal pharmaceuticals, overseas business, and bio business. The pharmaceutical division, which accounts for the largest share of sales, is further categorized into reimbursed drugs, non-reimbursed drugs, and obesity and well-being injections. In 2019, sales growth was driven by new reimbursed products.

Expected sales of approximately 2 billion won are projected from three products: "Hyaleum injection" for joint pain, "Newpogrel SR" effective for chronic arterial occlusion, and "NPiren S," a gastric mucosal protector. The launch of "Fine S," known for its effects on fat decomposition and sleep quality improvement, laid the foundation for growth in 2020. The company is also expanding its well-being injection field based on the immune booster "Thymosin," launched in the second half of 2018, and the functional medicine injection "Same injection," approved for depression.

Despite challenges from African swine fever and livestock market downturn, the animal pharmaceuticals division grew by over 10%, overcoming a 4% decline in the domestic market. High growth was achieved through the development of differentiated and functional new products, including large-scale swine growth promoters, an improved glutathione injection for stress relief in industrial animals, and differentiated mineral blocks stimulating digestion for Korean cattle.

The company plans to launch new products in the companion animal pharmaceuticals market continuously from the first half of 2020 and is working on differentiated formulation research and licensing in of European finished products.

In overseas business, Daehan New Pharm expects sales growth in 2020 through active promotion and marketing of its well-being and beauty-related products, showcased at the Manila and Indonesia Philbeauty fairs. Following successful exhibitions in Southeast Asia, the company plans to set up exhibitions and exclusive booths in the emerging Latin American market in the following year to actively promote its product excellence.